MSC2364447C Phase 1b in Systemic Lupus Erythematosus

Update Il y a 4 ans
Reference: NCT02537028

Woman and Man

Extract

The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic lupus erythematosus subjects (SLE).


Inclusion criteria

  • Lupus Erythematosus, Systemic

Links